Immunogenicity Reduction
Immunogenicity Reduction is a therapeutic antibody engineering and design strategy that systematically modifies antibody sequences, structures, or formulations to decrease their propensity to elicit undesired immune responses, such as anti-drug antibodies, while maintaining their intended biological function and clinical efficacy.
179
Publications
9.4K
Citations
1K
Authors
331
Institutions
Publications per year
2017–2026
35
Variants
Deimmunization
Parents
179
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Matthew Baker, Helen Reynolds, Brooke Lumicisi et al. · Self/Nonself · 2010 · 363 citations · Full text
IMMUNE RESPONSE TO CHEMICALLY MODIFIED FLAGELLIN
Christopher R. Parish · The Journal of Experimental Medicine · 1971 · 227 citations · Full text
Pharmacy, Biochemistry, Immunology +15
1–5 of 179
1K
5
h-index
4
h-index
4
h-index
4
h-index
4
h-index
1–5 of 1K
331
National Institutes of Health
Bethesda, United States
10 h-index
28 publications
2.6K citations
Harvard University
Cambridge, United States
9 h-index
20 publications
2.1K citations
University of Washington
Seattle, United States
7 h-index
34 publications
4.8K citations
National Institute of Allergy and Infectious Diseases
Bethesda, United States
6 h-index
16 publications
2K citations

Australian National University
Canberra, Australia
4 h-index
5 publications
701 citations
Inserm
Paris, France
4 h-index
8 publications
410 citations
Duke Medical Center
Durham, United States
4 h-index
12 publications
626 citations
University of North Carolina at Chapel Hill
Chapel Hill, United States
3 h-index
15 publications
405 citations
1–8 of 331
Repository · 12 publications · 407 citations
11
h-index
JI · 10 publications · 596 citations
10
h-index
9 publications · 340 citations
9
h-index
5 publications · 903 citations
5
h-index
5 publications · 191 citations
5
h-index
1–5